Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.
dc.contributor.author | Davidson, Brittany A | |
dc.contributor.author | Secord, Angeles Alvarez | |
dc.coverage.spatial | New Zealand | |
dc.date.accessioned | 2017-11-03T18:06:21Z | |
dc.date.available | 2017-11-03T18:06:21Z | |
dc.date.issued | 2014 | |
dc.description.abstract | Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Recently, clinical trials have focused on novel antiangiogenic agents in combination with chemotherapy or alone in women with primary and recurrent ovarian cancer. Antiangiogenic agents include monoclonal antibodies, tyrosine-kinase inhibitors, and peptibodies. Many of these agents, including bevacizumab, pazopanib, nintedanib, cediranib, and trebananib, have been evaluated in randomized Phase III clinical trials, and all have demonstrated a progression-free survival (PFS) benefit. Specifically, maintenance pazopanib was shown to improve PFS in women with newly diagnosed EOC. Pazopanib, an oral TKI, inhibits several kinase receptors, including those for vascular endothelial growth factor (-1,-2,-3), platelet-derived growth factor (-α and -β), and fibroblast growth factor. It also targets stem cell-factor receptor (c-kit), interleukin 2-inducible T-cell kinase, lymphocyte-specific protein tyrosine kinase, and colony-stimulating factor 1 receptor. Pazopanib has been investigated in several Phase II and III clinical trials, with results indicating a potential role in the management of EOC. This article provides an overview of pazopanib in the treatment of EOC. | |
dc.identifier | ||
dc.identifier | ijwh-6-289 | |
dc.identifier.issn | 1179-1411 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Informa UK Limited | |
dc.relation.ispartof | Int J Womens Health | |
dc.relation.isversionof | 10.2147/IJWH.S49781 | |
dc.subject | antiangiogenic agents | |
dc.subject | ovarian carcinoma | |
dc.subject | pazopanib | |
dc.title | Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer. | |
dc.type | Journal article | |
pubs.author-url | ||
pubs.begin-page | 289 | |
pubs.end-page | 300 | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Obstetrics and Gynecology | |
pubs.organisational-group | Obstetrics and Gynecology, Gynecologic Oncology | |
pubs.organisational-group | School of Medicine | |
pubs.publication-status | Published online | |
pubs.volume | 6 |
Files
Original bundle
- Name:
- Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.pdf
- Size:
- 900.32 KB
- Format:
- Adobe Portable Document Format
- Name:
- Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.pdf
- Size:
- 900.32 KB
- Format:
- Adobe Portable Document Format